DRMA — Dermata Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1853816 ·
Last close
$1.20
Market Cap
$4.83M
52W High
$1.84
52W Low
$1.10
ADV30
51,685
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -1,926,382 | -1,847,706 | 7,465,652 | 6,945,282 | — |
| Dec 2025 | 0 | — | -1,900,393 | -1,861,888 | 7,863,826 | 7,521,978 | 1,640,446 |
| Sep 2025 | 0 | — | -1,760,671 | -1,691,989 | 5,071,410 | 4,664,127 | 1,111,308 |
| Jun 2025 | 0 | — | -1,772,731 | -1,701,093 | 6,640,516 | 6,480,930 | 1,026,265 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-8,303,211
Investing CF
—
Financing CF
$5,529,225
CapEx
—
Dividends Paid
—
Buybacks
$-367
EPS Diluted TTM
$-8.26
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-75,081,602
Inventory
$93,091
Receivables
—
ST Investments
—
EBIT TTM
$-7,360,177
Pretax Income TTM
$-7,102,676
Interest Exp TTM
—
Analysts
1
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -7,773,598 | -7,558,557 | 7,863,826 | 1,640,446 | — | -7,757,559 |
| Dec 2024 | 0 | -12,513,242 | -12,287,461 | 3,533,888 | 1,972,794 | — | -11,162,948 |
| Dec 2023 | 0 | -8,041,906 | -7,794,690 | 7,978,634 | 1,623,616 | — | -6,408,931 |
| Dec 2022 | 0 | -9,674,486 | -9,610,913 | 6,944,488 | 922,634 | — | -8,834,164 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-3.87
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| MTNB | Matinas BioPharma Holdings, Inc. | $4.82M | $0.75 | — |
| SPRC | SciSparc Ltd. | $4.78M | $8.34 | — |
| PPCB | Propanc Biopharma, Inc. | $4.90M | $2.15 | — |
| RLFTF | MindMaze Therapeutics Holding SA | $4.72M | $0.38 | — |
| CVSI | CV Sciences, Inc. | $4.69M | $0.02 | — |
News headlines (Yahoo Finance, 1h cache)
Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the First Quarter 2026
2026-05-13 20:05 · Yahoo
Dermata Receives Notice of Acceptance of Australian Patent Application for Topical Application of Dermal Fillers with its Bioneedle Delivery System
2026-04-02 12:30 · Yahoo
Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Year Ended 2025
2026-03-26 21:15 · Yahoo
Dermata Announces Appointment of Kyra Peckaitis as Vice President, Marketing
2026-03-10 12:30 · Yahoo
Dermata Opens a New Chapter with the Release of Tome Skincare
2026-03-05 14:00 · Yahoo
Dermata Receives Notice of Grant of Patent for Next-Generation Acne Treatment by Australian Patent Office
2026-01-20 13:05 · Yahoo
Dermata Therapeutics Announces Closing of up to $12.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules
2025-12-29 21:05 · Yahoo
Dermata Therapeutics Announces up to $12.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules
2025-12-24 13:00 · Yahoo
A New Realm of Skincare is Coming: Dermata Teases New OTC Brand Identity
2025-12-04 13:00 · Yahoo
Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results
2025-11-14 21:05 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.